Henlius Present P-III Data of HLX02 (biosimilar- trastuzumab) at ESMO

Share this

Henlius Present P-III Data of HLX02 (biosimilar- trastuzumab) at ESMO


  • The P-III HLX02-BC01 study involves assessing HLX02 vs EU-sourced trastuzumab in combination with docetaxel in a 3wks. cycle for up to 1yr. in patients in a ratio (1:1) with HER2-positive recurrent/ mBC- prior not treated with systemic treatment  
  • Results:  Per ITT set- ORRwk24 (71.3% vs 71.4%); Per PP set- ORRwk24 (74.2% vs 73.2%); All subgroup analyses showed no statistically significant differences in ORR between the treatment groups in all populations- demonstrating the equivalence in efficacy
  • No difference between the two treatment groups in 2EPs- including CBR- DCR- DoR- PFS- and OS

­ Ref: Henlius | Image: Henlius

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions